CLSN
(NASDAQ)
2.76
+0.0509  (+1.85%)
Volume (24h): 279.17K Day Range: 2.68 - 2.83
Market Cap: 80.75M 52W Range: 0.6898 - 3.64
May-29-20 12:30PM Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian CancerGlobeNewswire
May-15-20 12:00PM Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire
May-08-20 01:00PM Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020GlobeNewswire
Apr-23-20 12:30PM Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection ProgramGlobeNewswire
Apr-17-20 02:04PM If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 97% Loss, TodaySimply Wall St.
Apr-15-20 12:30PM Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver CancerGlobeNewswire
Apr-04-20 10:13AM Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMTThomson Reuters StreetEvents
03:40AM Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMTThomson Reuters StreetEvents
Apr-02-20 01:44PM Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMTThomson Reuters StreetEvents
07:26AM Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMTThomson Reuters StreetEvents
Mar-27-20 01:39AM Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMTThomson Reuters StreetEvents
Mar-26-20 01:00PM Celsion Corp. to Host Earnings CallACCESSWIRE
12:00PM Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control ArmGlobeNewswire
Mar-25-20 08:15PM Celsion Corporation Reports 2019 Financial Results and Provides Business UpdateGlobeNewswire
Mar-23-20 12:00PM Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines AgencyGlobeNewswire
Mar-19-20 12:30PM Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020GlobeNewswire
12:00PM Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian CancerGlobeNewswire
Mar-03-20 01:30PM Celsion CEO Issues Letter to StockholdersGlobeNewswire
Feb-28-20 01:45PM Celsion Corporation Prices $4.8 Million Registered Direct OfferingGlobeNewswire
Feb-25-20 11:20AM When Can We Expect A Profit From Celsion Corporation (NASDAQ:CLSN)?Simply Wall St.
Feb-06-20 02:25PM Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian CancerGlobeNewswire
Feb-04-20 01:30PM Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology ConferenceGlobeNewswire
Jan-20-20 10:41AM Does Celsion Corporation (NASDAQ:CLSN) Have A High Beta?Simply Wall St.
Jan-15-20 09:34PM Alexion to Start Pivotal Study on Ultomiris for ALS in Q1Zacks
01:22PM Momenta (MNTA) Provides Pipeline Updates, Stock RalliesZacks
Jan-14-20 01:53PM Ultragenyx Provides Preliminary Crysvita 2019 RevenuesZacks
Jan-09-20 09:47PM Applied Therapeutics Up on Positive Galactosemia Study DataZacks
Jan-07-20 02:59PM Protagonist (PTGX) Starts Study on PTG-300 for Blood DisorderZacks
02:19PM aTyr (LIFE) Surges on Collaboration Deal With Kyorin PharmaZacks
Dec-23-19 07:15PM Hedge Funds Have Never Been This Bullish On Celsion Corporation (CLSN)Insider Monkey
Dec-18-19 01:00PM Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast AsiaGlobeNewswire
Dec-17-19 01:00PM Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) ProgramGlobeNewswire
Dec-15-19 01:10PM Should You Be Pleased About The CEO Pay At Celsion Corporation's (NASDAQ:CLSN)Simply Wall St.
Nov-30-19 06:48AM Edited Transcript of CLSN earnings conference call or presentation 15-Nov-19 4:00pm GMTThomson Reuters StreetEvents
Nov-14-19 09:05PM Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswire
01:00PM Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of HyperthermiaGlobeNewswire
Nov-09-19 01:40PM If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, TodaySimply Wall St.
Nov-08-19 01:30PM Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019GlobeNewswire
Nov-05-19 01:00PM Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian CancerGlobeNewswire
Nov-04-19 01:00PM Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver CancerGlobeNewswire
Oct-04-19 11:52AM Is Celsion (NASDAQ:CLSN) Using Debt In A Risky Way?Simply Wall St.
Oct-01-19 12:00PM Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive FundingGlobeNewswire
Sep-30-19 06:30PM Celsion to Present at the Chardan 3rd Annual Genetic Medicines ConferenceGlobeNewswire
Sep-23-19 12:00PM Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual ConferenceGlobeNewswire
Sep-04-19 10:32AM Market Sentiment Around Loss-Making Celsion Corporation (NASDAQ:CLSN)Simply Wall St.
Aug-27-19 12:00PM Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and TherapeuticsGlobeNewswire
Aug-23-19 09:40AM Edited Transcript of CLSN earnings conference call or presentation 15-Aug-19 3:00pm GMTThomson Reuters StreetEvents
Aug-14-19 08:30PM Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswire
Aug-13-19 12:01PM Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional RadiologyGlobeNewswire
Aug-09-19 12:30PM Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging OpportunitiesGlobeNewswire
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)